VTGN (Vistagen Therapeutics) Other Current Liabilities: $0.32 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VTGN Vistagen Therapeutics Inc VTGN
16 GF Score
Price $0.24
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Other Current Liabilities?

Vistagen Therapeutics VTGN +3.53% 16 Other Current Liabilities is $0.32 Mil as of Mar. 2026. GuruFocus rates VTGN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review.

Vistagen Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was $0.32 Mil.

Vistagen Therapeutics's quarterly other current liabilities declined from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($-0.00 Mil) but then increased from Dec. 2025 ($-0.00 Mil) to Mar. 2026 ($0.32 Mil).

Vistagen Therapeutics's annual other current liabilities increased from Mar. 2024 ($1.62 Mil) to Mar. 2025 ($3.36 Mil) but then declined from Mar. 2025 ($3.36 Mil) to Mar. 2026 ($0.32 Mil).

Vistagen Therapeutics Other Current Liabilities Related Terms

Vistagen Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Other Current Liabilities Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.34 1.62 3.36 0.32

Vistagen Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.36 0.00 0.00 -0.00 0.32
VTGN
16GF Score
Vistagen Therapeutics Inc VTGN
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.32 Mil mean?
Vistagen Therapeutics (VTGN) has a Other Current Liabilities of $0.32 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vistagen Therapeutics.
Is Vistagen Therapeutics' Other Current Liabilities too high?
Vistagen Therapeutics' current Other Current Liabilities is $0.32 Mil. Overall, Vistagen Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Other Current Liabilities compare to ASBP and CRIS?
Vistagen Therapeutics' Other Current Liabilities of $0.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vistagen Therapeutics. Vistagen Therapeutics's current Other Current Liabilities is $0.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (VTGN) has a current Other Current Liabilities of $0.32 Mil. The current Other Current Liabilities is $0.32 Mil. Vistagen Therapeutics' overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Vistagen Therapeutics (VTGN), the current Other Current Liabilities is $0.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vistagen Therapeutics Business Description

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
16GF Score

Get the complete analysis for VTGN

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price